Cencora (COR) announced a new segment reporting structure, effective beginning in the first fiscal quarter of 2027, after completing the restructuring of its operating model. The company will report the Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other segments. According to the company, the change aims to strengthen execution and improve visibility.
The Pharmaceutical Distribution and Services segment will bring together wholesale pharmaceutical distribution in the US and abroad and related services, serving health systems, retail pharmacies and alternate care sites. Specialty Pharmaceutical and Provider Services will include specialty distribution services to physician practices and management services organizations, World Courier and third-party logistics (3PL) services, Innomar and strategic components of PharmaLex. The Other category, which is not a reportable segment, will group businesses for which the company is evaluating strategic alternatives: MWI Animal Health, Profarma and the remaining PharmaLex components.
To help investors, Cencora released unaudited data revised for the new structure. In the fiscal year ended September 30, 2026, total revenue was US$ 337.4 bn, up from US$ 321.3 bn in fiscal 2025. Total segment operating income was US$ 4.8 bn, up from US$ 4.2 bn.
Pharmaceutical Distribution and Services had revenue of US$ 284.5 bn and operating income of US$ 2.7 bn in fiscal 2026, with an operating margin of 0.96%. Specialty Pharmaceutical and Provider Services posted revenue of US$ 45.4 bn and operating income of US$ 1.7 bn, with a margin of 3.73%, compared with 3.22% the previous year. Other recorded revenue of US$ 8.7 bn and operating income of US$ 392.9 mn.
